Bayer HealthCare Animal Health Division has Fido and Bessie's wellness in mind. The company is part of the health care division of global chemical and pharmaceutical giant Bayer. The Animal Health Division manufactures anti-infectives, insecticides, parasiticides, sedatives, nutritional supplements, vaccines, and other pharmaceuticals for companion (dogs, cats, horses) and farm (cattle, pigs, poultry, bees) animals. Major products include flea and heartworm treatment Advantage and anti-infective Baytril. The division operates more than 50 branch locations worldwide and sells its products in some 120 countries.

Transcept Pharmaceuticals, Inc. (Transcept) is a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in the field of neuroscience. The lead Transcept product candidate, Intermezzo, is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. The Company has completed all scheduled clinical trials on behalf of Intermezzo and submitted a New Drug Application (NDA), to the United States Food and Drug Administration (FDA), on September 30, 2008, which was accepted for filing on December 15, 2008. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to Transcept Pharmaceuticals, Inc.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

BioGenex Laboratories, Inc. company was founded in 1981 and is based in San Ramon, California. BioGenex Laboratories Inc provides automated systems that streamline operations in molecular and cellular pathology laboratories. It offers Xmatrx Dx, an automated staining system that includes detection kits, primary antibodies, probes, reagents, and consumables for immunohistochemistry (IHC), in situ hybridization (ISH) and special stains (SS); i6000 that is an automated staining system designed for clinical diagnostics and research laboratories; EZ-Retriever System v.2, a microwave-based time and temperature controlled system designed to unmask the antigens on the formalin-fixed paraffin-embedded (FFPE) tissue sections; i500 Integrated Labeling System, a portable barcode solution, which creates barcode and text labeling for histology and cytology slides; and Xmatrx Rx, a biomarker assay development and analysis system that offers possibilities for translational and clinical research. The company also provides antibodies, antigen retrieval, ancillary reagents, detection systems, special stains, and tissue controls. In addition, it provides DNA/RNA synthesis labeling reagents, phosphoramidite, and branching phosphoramidites. The company serves reference laboratories, hospital laboratories, cancer treatment centers, university medical centers, group practices, and drug discovery laboratories in pharmaceutical and biotechnology firms, as well as oligonucleotide houses and academic institutions. BioGenex Laboratories Inc markets its products through distributors in Africa, Asia, Australia, Europe, the Middle East, North America, and South America.

Ranbaxy UK Ltd. company began its operations in Britain in 1994. Ranbaxy UK hopes to run the British generic pharmaceuticals market. Ranbaxy company, a subsidiary of Indian drug firm Ranbaxy Laboratories, offers a wide variety of generic drugs in the UK for central nervous system disorders, cardiovascular diseases, and anti-infectives. Some of the company's products include Easyhaler (an inhaler for respiratory problems), Visclair (for chronic obstructive pulmonary disease), and Distaclor-MR (for respiratory tract infections). Ranbaxy UK represents a major foothold for the group's operations in Europe.

Synbiotics is concerned with the conditions of cats, cows, canines, and other critters. The company provides diagnostic products for the animal health care industry worldwide, through facilities in the US and France. Its canine reproduction services division trains vets in canine reproductive services, including artificial insemination, and runs the Canine Freezing Center Network, which operates what Synbiotics says is the largest bank of frozen canine semen in the world. Synbiotics company also develops and markets test kits for animal parasites, pregnancy, viruses, and other diseases and conditions in the animal kingdom. Its test for bird flu, the FluDetect Avian Influenza Type A antigen kit, is sold globally.

Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

lmmuCell Corporation company was founded in 1982 and is based in Portland, Maine. ImmuCell Corporation, an animal health biotechnology company, engages in the development, manufacture, and sale of products that improve animal health and productivity in the United States and internationally. It offers First Defense, an orally delivered scours preventive product that is manufactured from cows colostrums using proprietary vaccine and milk protein purification technologies. The company also provides products that aid in the management of inflammation of the mammary gland caused by bacterial infections, including Wipe Out Dairy Wipes, which consist of pre-moistened, biodegradable towelettes that are impregnated with Nisin to prepare the teat area of a cow in advance of milking; MASTiK, a mastitis antibiotic susceptibility test kit; and California Mastitis Test (CMT), which is performed at cow-side for early detection of mastitis. CMT can be used for bulk tank and individual cow sample monitoring, and for determining the quarter of the udder that is mastitic. In addition, it offers Rapid Johne's Test, which identifies cattle with symptomatic Johne's disease in a herd. Additionally, ImmuCell Corporation focuses on developing Mast Out, an intramammary infusion product containing Nisin for use in the treatment of mastitis in lactating dairy cows. It sells and markets its products primarily to veterinarians and producers in the dairy and beef industries.

Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.